Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood

Virology

Volumn 312, Issue 2, 2003, Pages 495-506

  Ovsyannikova, Inna G ^a   Johnson, Kenneth L ^a   Naylor, Stephen ^a,b   Muddiman, David C ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b Beyond Genomics   (United States)

Author keywords

HLA DRB1*03; Lymphocyte proliferation; Mass spectrometry; Measles virus; Measles derived peptide

Indexed keywords

ALANYLSERYLASPARTYLVALYLGLUTAMYLTHREONYLALANYLGLUTAMYLGLYCYLGLYCYLGLUTAM YLI SOLEUCYLHISTIDYLGLUTAMYLLEUCYLARGINYLLEUCYLGLUTAMINE; HLA DR ANTIGEN; MEASLES VACCINE; PEPTIDE; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG DESIGN; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MASS SPECTROMETRY; MEASLES; MEASLES VIRUS; MOLECULAR RECOGNITION; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE HOMOLOGY; T LYMPHOCYTE;

MEASLES VIRUS;

EID: 0041561072     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00281-2     Document Type: Article

References (45)

1. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months mechanism of measles vaccine failure . J. Pediatr. 91:1977;715-718.
2. Bakouche O., Mougin B., Gerlier D. In vitro cellular immune response to measles viral glycoproteins role of the antigen vector . Immunology. 62:1987;605-611.
3. Bautista-López N., Ward B.J., Mills E., McCormick D., Martel N., Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine. 18:2000;1393-1401.
4. Brinckmann U.G., Bankamp B., Reich A., ter Meulen V., Liebert U.G. Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. J. Gen. Virol. 72:1991;2491-2500.
5. Brown J.H., Jardetzky T., Saper M.A., Samraoui B., Bjorkman P.J., Wiley D.C. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 332:1988;845-850.
6. de Jong A. Contribution of mass spectrometry to contemporary immunology. Mass Spectrom. Rev. 17:1998;311-335.
7. Dongre A.R., Kovats S., deRoos P., McCormack A.L., Nakagawa T., Paharkova-Vatchkova V., Eng J., Caldwell H., Yates J.R. III, Rudensky A.Y. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur. J. Immunol. 31:2001;1485-1494.
8. Doolan, D.L., Southwood, S., Chesnut, R., Appella, E., Gomez, E., Richards, A., Higashimoto, Y.I., Maewal, A., Sidney, J., Gramzinski, R.A., Mason, C., Koech, D., Hoffman, S.L., Sette, A., (2000). HLA-DR promiscuous T cell epitopes from Plasmodium falciparum ore-erythrocytic-state antigens restricted by multiple HLA Class II alleles. J. Immunol. 1123-1137.
9. El Kasmi K.C., Fillon S., Theisen D.M., Hartter H., Brons N.H.C., Muller C.P. Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies. J. Gen. Virol. 81:2000;729-735.
10. El Kasmi K.C., Theisen D., Brons N.H.C., Ammerlaan W., Klingele M., Truong A.T., Muller C.P. A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis. Vaccine. 17:1999;2436-2445.
11. Eng J.K., McCormack A.L., Yates J.R. III. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Am. Soc. Mass Spectrom. 5:1994;976-989.
12. Garcia K.C., Teyton L., Wilson I.A. Structural basis of T cell recognition. Annu. Rev. Immunol. 17:1999;369-397.
13. Gellin B.G., Katz S.L. Measles state of the art and future directions . J. Infect. Dis. 170:1994;S3-S14.
14. Germain R.N., Hendrix L.R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 353:1991;134-139.
15. Germain R.N. MHC-dependent antigen processing and peptide presentation providing ligands for T lymphocyte activation . Cell. 76:1994;287-299.
16. Germain R.N. Modern concepts in immune recognition and lymphocyte activation relevance for the development of useful vaccines . Int. J. Technol. Assess. Health Care. 10:1994;81-92.
17. Germain R.N. The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines. Ann. NY Acad. Sci. 754:1995;114-125.
18. Griffin D.E., Bellini W.J. Measles virus. Fields B.N., Knipe D.M., Howley P.M. Fields Virology. 1996;1267-1312 Lippincott-Raven, Philadelphia.
19. Herberts C.A., Stittelaar K.J., van der H.E., van Gaans-Van den Brink J., Poelen M.C.M., Roholl P.J.M., van Alphen L.J.W., Melief C.J.M., de Jong A.P.J.M., van Els C.A.C.M. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. J Gen. Virol. 82:2001;2131-2142.
20. Horikami S.M., Moyer S.A. Structure, transcription, and replication of measles virus. Curr. Top. Microbiol. Immunol. 191:1995;35-50.
21. Jacobson S., Sekaly R.P., Jacobson C.L., McFarland H.F., Long E.O. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J. Virol. 63:1989;1756-1762.
22. Jaye A., Magnusen A.F., Sadiq A.D., Corrah T., Whittle H.C. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J. Clin. Invest. 102:1998;1969-1977.
23. Kirschmann D.A., Duffin K.L., Smith C.E., Welply J.K., Howard S.C., Schwartz B.D., Woulfe S.L. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. J. Immunol. 155:1995;5655-5662.
24. Lampson L.A., Levy R. Two populations of Ia-like molecules on human B cell line. J. Immunol. 125:1980;293-299.
25. Link A.J., Eng J., Schieltz D.M., Carmack E., Mize G.J., Morris D.R., Garvik B.M., Yates J.R. III. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17:1999;676-682.
26. Marttila J., Ilonen J., Norrby E., Salmi A. Characterization of T cell epitopes in measles virus nucleoprotein. J. Gen. Virol. 80:1999;1609-1615.
27. Naniche D., Varior-Krishnan G., Cervoni F., Wild T.F., Rossi B., Rabourdin-Combe C., Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:1993;6025-6032.
28. Neitzel H. A routine method for the establishment of permanent growing lymphoblastiod cell lines. Hum. Genet. 73:1986;320-326.
29. Nuchtern J.G., Biddison W.E., Klausner R.D. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 343:1990;74-76.
30. Ovsyannikova I.G., Johnson K.L., Naylor S., Poland G.A. Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection. J. Immunol. Methods. 246:2000;1-12.
31. Pamer E.G. Antigen presentation in the immune response to infectious diseases. Clin. Infect. Dis. 28:1999;714-716.
32. Parks C.L., Lerch R.A., Walpita P., Wang H.-P., Sidhu M.S., Udem S.A. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J. Virol. 75:2001;910-920.
33. Patterson J.B., Thomas D., Lewicki H., Billeter M.A., Oldstone M.B. V and C proteins of measles virus function as virulence factors in vivo. Virology. 267:2000;80-89.
34. Peakman M., Stevens E.J., Lohmann T., Narendran P., Dromey J., Alexander A., Tomlinson A.J., Trucco M., Gorga J.C., Chicz R.M. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J. Clin. Invest. 104:1999;1449-1457.
35. Poland G.A., Jacobson R.M., Schaid D., Jacobsen S.J. Immunogenetic mechanisms of antibody response to measles vaccine the role of the HLA genes . Vaccine. 17:1999;1719-1725.
36. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Schaid D.J. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine. 20:2001;430-438.
37. Poland G.A., Ovsyannikova I.G., Johnson K.L., Naylor S. The role of mass spectrometry in vaccine development. Vaccine. 19:2001;2692-2700.
38. Sabin A.B. Measles, killer of millions in developing countries strategy for rapid elimination and continuing control . Eur. J. Epidemiol. 7:1991;1-22.
39. Sekaly R.P., Jacobson S., Richert J.R., Tonnelle C., McFarland H.F., Long E.O. Antigen presentation to HLA class II-restricted measles virus-specific T-cell clones can occur in the absence of the invariant chain. Proc. Natl. Acad. Sci. USA. 85:1988;1209-1212.
40. Smith R.D., Anderson G.A., Lipton M.S., Pasa-Tolic L., Shen Y., Conrads T.P., Veenstra T.D., Udseth H.R. An accurate mass tag strategy for quantitative and high-throughout proteome measurements. Proteomics. 2:2002;513-523.
41. Spahr C.S., Davis M.T., McGinley M.D., Robinson J.H., Bures E.J., Beierle J., Mort J., Courchesne P.L., Chen K., Wahl R.C., Yu W., Luethy R., Patterson S.D. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics. 1:2002;93-107.
42. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215-221.
43. van Binnendijk R.S., Versteeg-van Oosten J.P.M., Poelen M.C.M., Brugghe H.F., Hoogerhout P., Osterhaus A.D.M.E., Uytdehaag F.G.C.M. Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J. Virol. 67:1993;2276-2284.
44. van Els C.A.C.M., Herberts C.A., van der Heeft E., Poelen M.C.M., van Gaans-van den Brink J.A.M., van der Kooi A., Hoogerhout P., ten Hove G.J., Meiring H.D., de Jong A.P.J.M. A single naturally processed measles virus peptide fully dominates the HLA-A*00201-associated peptide display and is mutated at its anchor position inpersistent viral strains. Eur. J. Immunol. 30:2000;1172-1181.
45. Washburn M.P., Wolters D., Yates J.R. III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19:2001;242-247.